Table 2.

Schedule of assessments during trial period

	Day 0	Day 1	Days 2–3	Day 4	Days 5–6	Day 7	Days 8–13	Day 14	Days 15–28	Day 90 (± 14 days)	1 year (± 30 days)	2 years (± 30 days)
Eligibility assessment	X
Informed consent	X
Enrolment/randomisation	X
Baseline data	X
Daily data		X	X	X	X	X	X	X
Chlorphenamine administration		X
IMP administration		X
Adverse events		X	X	X	X	X	X	X	X	X
ECHO data (phase 2 only)	X			X
BAL sampling (where possible)	X			X
Blood sampling	X			X		X		X			X	X
Anti-HLA Ab	X								X
Urine sampling	X			X		X		X
Mortality									X	X	X	X
Medical event											X	X